StockVS

IRADIMED CORPORATION (IRMD) Aandelenanalyse

Gezondheidszorg

IRADIMED CORPORATION

$92.94

+$0.84 (+0.91%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

IRADIMED CORPORATION is engaged in the development, manufacturing, marketing, and distribution of specialized medical equipment designed for environments requiring magnetic resonance imaging compatibility. Specifically, the firm provides MRI compatible intravenous infusion pump systems and patient vital signs monitoring systems, along with associated accessories such as the MRidium 3870 and 3860+ models. This entity operates within the Healthcare sector, specifically targeting the Medical Devices industry, a segment characterized by rigorous regulatory standards and a focus on advanced technological integration for patient care. The company maintains a market capitalization of $1.19B and generates annual revenue of $83.81M while employing 166 individuals. These valuation and revenue figures indicate that the organization holds a significant position within its niche, possessing a market cap that suggests strong investor confidence relative to its current sales output, reflecting a mature yet specialized operational scale.

Financiële gezondheid

The company reported a Total Revenue of $83.81M over the trailing twelve months, generating a Net Income of $22.48M and an EBITDA of $27.31M. The substantial gap between revenue and net income reveals a highly efficient cost structure where operating expenses and taxes consume approximately 73.2% of total sales, leaving a robust bottom line. Free Cash Flow stands at $6.64M, which indicates that the company generates sufficient cash from operations to fund internal projects and maintain liquidity without relying heavily on external financing. The Gross Margin is reported at 76.7%, signaling strong pricing power and high efficiency in production or low cost of goods sold relative to the premium nature of the devices. Operating Margin reaches 31.3%, demonstrating effective management of overhead costs, while the Profit Margin sits at 26.8%, confirming that a significant portion of every dollar in revenue translates to actual profit. The firm holds $51.16M in cash against $0 in debt, resulting in a Debt to Equity ratio that is effectively N/A due to the absence of liabilities, which portrays a conservative and highly leveraged-free balance sheet. Furthermore, the Current Ratio is 7.98, a metric that indicates an exceptionally strong short-term liquidity position where current assets vastly exceed current liabilities. Return on Equity is 24.8% and Return on Assets is 15.8%, metrics that reveal management effectiveness in generating high returns on the shareholders' capital and the company's total asset base respectively.

Waarderingsbeoordeling

The Trailing P/E Ratio is 53.37, while the Forward P/E is 40.26. The notable difference between these two ratios implies that the market expects earnings growth in the future, as analysts project a lower multiple based on anticipated higher profitability in upcoming periods. The Price to Book ratio is 12.62, which indicates a significant market premium over the company's book value, suggesting investors are willing to pay a high multiple for the firm's tangible assets and intangible brand value. Additionally, the Price to Sales ratio is 14.24 and the EV/EBITDA stands at 41.84, metrics that suggest the stock is priced at a premium relative to its revenue generation and earnings capacity compared to historical averages. Regarding price volatility, the stock has a 52-Week High of $107.90 and a 52-Week Low of $50.00. Without a specific current share price provided in the facts, the range demonstrates a total trading swing of approximately 54.1%, highlighting the asset's potential for significant price appreciation or depreciation within a single year. The Beta is 1.12, meaning the stock's price volatility is 12% higher than the broader market, indicating it is more sensitive to market fluctuations than the average stock.

Growth & Income

Revenue Growth over the last year is 17.0%, while Earnings Growth is 24.8%. The fact that earnings are growing faster than revenue implies that the company is improving its profitability through cost synergies, price increases, or operational efficiencies rather than relying solely on volume expansion. As a dividend payer, the company offers a Dividend Yield of 0.9% with a Payout Ratio of 38.9%. This payout ratio is considered sustainable given the company's earnings growth rate, as retaining over half of the earnings allows for continued reinvestment while rewarding shareholders. The combination of double-digit revenue expansion and earnings outpacing sales, alongside a sustainable dividend yield, summarizes the overall growth and income profile as one of balanced expansion with a commitment to returning capital to investors.

Vergelijking met sectorgenoten

IRADIMED CORPORATION (IRMD) is actief in de Medische Apparatuur-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
IRADIMED CORPORATION IRMD $1.19B 50.8
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

De gemiddelde K/W-verhouding in de Medische Apparatuur-sector is 60.2x. IRADIMED CORPORATION wordt verhandeld tegen een K/W van 50.8.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over IRADIMED CORPORATION

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$1.19B
K/W-verhouding
50.79
52-weken hoog
$107.90
52-weken laag
$51.34
Gem. Volume
106.52K
Bèta
0.91
Dividendrendement
0.86%

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
United States
Werknemers
166